Dr. Samir Tari is the global medical lead responsible for the retinal cell and gene therapy projects at Astellas Pharma Inc. and Astellas Institute for Regenerative Medicine, respectively. Prior to joining Astellas, Dr. Tari was the clinical strategy lead for the Humira Uveitis program at AbbVie, where he led the team that obtained the first FDA approval of a non-steroidal treatment for non-infectious uveitis. Prior to AbbVie, Dr. Tari was involved in several startups both as a founder and employee. Dr. Tari received his medical training at Cairo University and fellowships in basic science, translational, and clinical research at Columbia University and New York Eye and Ear Infirmary. Dr. Tari also received his MBA from University of Chicago Booth School of Business.